Latest Articles

Publication Date
Single-cell analysis identifies distinct macrophage phenotypes associated with prodisease and proresolving functions in the endometriotic niche.

Endometriosis negatively impacts the health-related quality of life of 190 million women worldwide. Novel advances in nonhormonal treatments for this debilitating condition are desperately needed. Macrophages play a vital role …

Published: Sept. 10, 2024, midnight
R-954, a bradykinin B1 receptor antagonist, as a potential therapy in a preclinical endometriosis model.

Endometriosis is a gynecological condition characterized by the growth of endometrium-like tissues outside of the uterine cavity. Currently available drugs are efficacious in treating endometriosis-related pain, however it's not a …

Published: Sept. 10, 2024, midnight
Origin of Peritoneal Cancer With Features of High-grade Serous Carcinoma: A Detailed Molecular Analysis.

Primary peritoneal cancer has characteristics similar to high-grade serous carcinomas of ovarian and fallopian tube origin. However, the relationship between endometriosis and primary peritoneal cancer is not well understood. This …

Published: Sept. 10, 2024, midnight
Clinicopathological features of endometriosis‑associated adenocarcinoma of the rectum: A report of two cases.

Endometriosis-associated adenocarcinoma of the rectum is rare and is usually misdiagnosed as colorectal carcinoma or other gynecological tumors. In the current report, the clinicopathological features of endometriosis-associated adenocarcinoma of the …

Published: Aug. 30, 2024, midnight
Two Cases of Symptomatic Tailgut Cysts.

Tailgut cysts are rare lesions which are found in the rectorectal space. They develop in the final section of the intestine from which the rectum and anus extend and vary …

Published: Aug. 29, 2024, midnight
MSK Endometrial Cancer e-Tumor Board - Medscape

MSK Endometrial Cancer e-Tumor Board Medscape

Published: July 12, 2024, 7 a.m.
AstraZeneca, Daiichi Sankyo's Enhertu wins historic HER2 tumor-agnostic FDA nod - FiercePharma

AstraZeneca, Daiichi Sankyo's Enhertu wins historic HER2 tumor-agnostic FDA nod FiercePharma

Published: April 8, 2024, 7 a.m.
Melatonin: Current evidence on protective and therapeutic roles in gynecological diseases.

Melatonin, a potent antioxidant and free radical scavenger, has been demonstrated to be effective in gynecological conditions and female reproductive cancers. This review consolidates the accumulating evidence on melatonin's multifaceted …

Published: March 11, 2024, midnight
CLDN6-23-ADC shows promise for ovarian, endometrial tumors - BioWorld Online

CLDN6-23-ADC shows promise for ovarian, endometrial tumors BioWorld Online

Published: Feb. 29, 2024, 8 a.m.
The P286R mutation of DNA polymerase ε activates cancer-cell-intrinsic immunity and suppresses endometrial tumorigenesis via the cGAS-STING pathway | Cell Death & Disease - Nature.com

The P286R mutation of DNA polymerase ε activates cancer-cell-intrinsic immunity and suppresses endometrial tumorigenesis via the cGAS-STING pathway | Cell Death & Disease Nature.com

Published: Jan. 18, 2024, 8 a.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!